<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870844</url>
  </required_header>
  <id_info>
    <org_study_id>12053A</org_study_id>
    <secondary_id>2007-003390-81</secondary_id>
    <nct_id>NCT00870844</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO)
      dosed once daily for 5 days is a safe treatment for patients who have suffered an acute
      ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute ischemic stroke is a major cause of death and severe disability. The naturally
      occurring hormone, erythropoietin (EPO), is able to protect various neuronal tissues from
      ischemic injury and is beneficial in animal models of acute ischemic stroke. Lu AA24493 is a
      modified (carbamylated) version of EPO, neuroprotective but without the haematopoietic side
      effects. Lu AA24493 is developed for treatment of patients with acute ischemic stroke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS)</measure>
    <time_frame>NIHSS = Baseline: Day 2, 3, 4, 5, Day 6/Discharge, Day 14, 30. mRS = Baseline, Day 6/Discharge, Day 14, 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, immunogenicity and biomarkers</measure>
    <time_frame>Baseline, Days 1-6, Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 0.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 5.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24493 (CEPO): 50.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AA24493 (CEPO)</intervention_name>
    <description>0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset</description>
    <arm_group_label>Lu AA24493 (CEPO): 0.5 mcg/kg</arm_group_label>
    <arm_group_label>Lu AA24493 (CEPO): 5.0 mcg/kg</arm_group_label>
    <arm_group_label>Lu AA24493 (CEPO): 50.0 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vials with solution for IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 50 and 90 years

          -  Clinical diagnosis of acute ischemic stroke

          -  Measurable stroke-related deficit

          -  Patient is stable

          -  Treatment can be initiated between 0 hours and 48 hours after the onset of stroke

          -  Expected hospital stay of at least 120 hours after first dose of study medication

          -  If female then not of childbearing potential

        Exclusion Criteria:

          -  Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of
             infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH),
             arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm

          -  Treated with a thrombolytic &lt;24 hours (if &gt;24 hours and excluded ICH then eligible)

          -  Score &gt;=1 on the NIHSS item 1a

          -  Pre-stroke mRS score &gt;=2

          -  Uncontrolled hypertension

          -  Previous treatment with erythropoietin

          -  Previous exposure to Lu AA24493
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FI004</name>
      <address>
        <city>Helsinki</city>
        <zip>29</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR002</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NL005</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SG003</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GB001</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>April 19, 2011</last_update_submitted>
  <last_update_submitted_qc>April 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>H. Lundbeck A/S</name_title>
    <organization>H. Lundbeck A/S</organization>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Carbamylated</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

